Page 84 - 81_04
P. 84
Tuberculosis is not an illness of the past
O OO O OO
O O ATP ADP H PO
O PO OO
NH3 O
O O NH3 H2N O
NH3 O
NH3
Glutamato
OO O
H NH2 HO P O
O
NH3 O
Glutamina
Figura 19. Mecanismo de acción de glutamina sintetasa MtGS.
Database of Systematic Reviews 2003;
Ensayos in vivo con cobayas infectados con Mtb GS DOI: 10.1002/14651858.CD001166.
demostraron que el análogo de glutamato metionina-SR- 8. a) Cardona PJ. Robert Koch tenía razón. Hacia una
sulfoximina (MSO, Figura 20), un inhibidor de MtGs, nueva interpretación de la terapia con tuberculina.
protege a los animales de la pérdida de peso característica Enferm Infecc Microbiol Clin 2006; 24: 385-91. b)
de la tuberculosis y del crecimiento del bacilo en distintos Cardona PJ, Amat I. Origen y desarrollo de RUTI, una
órganos. MSO actúa sinérgicamente con isoniazida (78). nueva vacuna terapéutica contra la infección por
O O Mycobacterium tuberculosis. Arch Bronconeumol
O S 2006; 42: 25-32.
NH 9. Amberson J, McMahon B, Pinner M. A clinical trial of
H 3N CH3 sanocrysin in pulmonary tuberculosis. Am Rev
Tuberculosis 1931; 24: 401-35.
Metionina-SR-sulfoximina 10. Feldman WH, Hinshaw HC, Mann FC. Promizole in
Figura 20. Estructura del ibhibidor de MtGS metionina-SR- tuberculosis. Am Rev Tuberculosis 1944; 50: 418-40.
sulfoximina. 11. The Therapeutic Trials Committee of the Swedish
8. REFERENCIAS National Association against Tuberculosis. Para-
aminosalicylic acid treatment in pulmonary
1. Cole ST. Comparative and functional genomics of the tuberculosis. Am Rev Tuberc 1950; 61: 597-612.
Mycobacterium tuberculosis complex. Microbiology
2002; 148: 2919-28. 12. Fox W, Sutherland I. A five-year assessment of
patients in a controlled trial of streptomycin, para-
2. Heifets L. Mycobacterial infections other than aminosalicylic acid, and streptomycin plus para-
tuberculosis and leprosy (Infections caused by aminosalicylic acid, in pulmonary tuberculosis. Q J
nontuberculous Mycobacteria-NTM). Sem Resp Crit Med 1956; 25: 221-43.
Care Med 2004; 25: 283-96.
13. McDermott W. Antimicrobial therapy of pulmonary
3. Comas I, Coscolla M, Luo T, et al. Out of Africa tuberculosis. Bull World Health Organ 1960; 23: 427-
migration and Neolithic coexpansion of 61.
Mycobacterium tuberculosis with modern humans.
Nature Genet 2013; 45: 1176-82. 14. Shepherd RG, Wilkinson RG. Antituberculous agents
II. N,N'-diisopropylethylenediamine and analogs. J
4. Brock TD. Robert Koch, a life in medicine and Med Pharm Chem 1962; 91: 823-35.
bacteriology. Washington: ASM Press 1999.
15. Andriole VT. The Quinolones: Past, Present, and
5. Ver por ejemplo: a) Ryan F. Tuberculosis: The greatest Future. Clin Infect Dis 2005; 41: S113-S119.
story never told. Swift Publishers Ltd 1992. b)
Murphy J, Blank A. Invincible Microbe: Tuberculosis 16. Tsukamura M, Nakamura E, Yoshii S, Amano H.
and the Never-Ending Search for a Cure. Harcourt Therapeutic effect of a new antibacterial substance
Brace and Company 2015. ofloxacin (DL8280) on pulmonary tuberculosis. Am
Rev Respir Dis 1985; 131: 352-6.
6. a) McMurray DN. Impact of nutritional deficiencies on
resistance to experimental pulmonary tuberculosis. 17. Singh J, Cameron Ch, Noorbaloochi S, et al. Risk of
Nutr Rev 1998; 56: S147–52. b) Chocano-Bedoya P, serious infection in biological treatment of patients
Ronnenberg AG. Vitamin D and tuberculosis. Nutr with rheumatoid arthritis: a systematic review and
Rev 2009; 67: 289-93. c) Green M. Cod liver oil and meta-analysis. Lancet 2015; 386: 258-65.
tuberculosis. BMJ 2011; 343: d7505.
18. Dunlap NE, Bass J, Fujiwara P, et al. Diagnostic
7. Bruyn G, Garner P. Mycobacterium vaccae standards and classification of tuberculosis in adults
immunotherapy for treating tuberculosis. Cochrane and children. Am J Respir Crit Care Med 2000; 161:
1376-95.
@Real Academia Nacional de Farmacia. Spain 353
